Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 647-658 , December 2008

Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?

  • Dan Douer, MD (Associate Professor of Medicine, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA)

      Affiliations

    • Corresponding Author InformationTel.: +1 323 865 3950; Fax: +1 323 865 0060.

References 

  1. Kurtzberg J. Asparaginase. In:  Holland JF,  Bast RCJ,  Morton DL, et al. editor. Cancer medicine. Baltimore, MD: Williams and Wilkins; 1997;p. 1027
  2. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71:123–131
  3. Goekbuget N, Arnold R, Buechner T, et al. Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93. Blood. 2001;98:802a;[abstract 3338]
  4. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025–2037
  5. Stock W, Johnson J, Yu D, et al. Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): vinal results from Cancer and Leukemia Group B Study 19802. Blood. 2005;106:521a;[Abstract 1833]
  6. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–1833
  7. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–2801
  8. Haskell CM, Canellos GP. l-asparaginase resistance in human leukemia–asparagine synthetase. Biochemical Pharmacology. 1969;18:2578–2580
  9. Cooney DA, Handschumacher RE. L-asparaginase and L-asparagine metabolism. Annual Review of Pharmacology. 1970;10:421–440
  10. Nandy P, Periclou AP, Avramis VI. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0) and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis. Anticancer Research. 1998;18:727–737
  11. Ertel IJ, Nesbit ME, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from childrens cancer study group. Cancer Research. 1979;39:3893–3896
  12. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. The American Journal of Pediatric Hematology/Oncology. 1979;1:9–13
  13. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982;49:378–1383
  14. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood. 2000;96:1709–1715
  15. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511. Blood. 2007;109:4164–4167
  16. Avramis VI, Holcenberg JS, Ettinger AG, et al. Failure of asparagine (ASN) depletion, not inadequate asparaginase (ASNase) activity, predicts relapse in standard risk (SR) childhood Acute Lymphoblastic Leukemia (ALL): a Childrens Oncology Group (COG) report. Blood. 2007;110:181a;[abstract 588]
  17. Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998;12:660–665
  18. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 2000;18:1525–1532
  19. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children's cancer group study CCG-1961. Journal of Pediatric Hematology/Oncology. 2004;26:217–226
  20. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Research. 1983;43:5601–5607
  21. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211–1218
  22. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 2005;23:7161–7167
  23. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. The New England Journal of Medicine. 1998;338:1663–1671
  24. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM study group. Blood. 2000;95:3310–3322
  25. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122–3133
  26. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548–2555
  27. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-Asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99:2734–2739
  28. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896–904
  29. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750
  30. Srivastava P, Watkins K, Mark L, et al. Treatment of adults with newly diagnosed acute lymphoblastic leukemia with multiple doses of intravenous pegylated asparaginase in an intensified pediatric regimen. Haematologica. 2008;93:366;[abstract 920]
  31. DeAngelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood. 2007;110:181a;[abstract 587]
  32. Combination chemotherapy in treating young patients with newly diagnosed acute lymphoblastic leukemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00558519[accessed 18.07.08]
  33. Phase III randomized study of dexamethasone versus prednisone during induction and high-dose methotrexate with leucovorin rescue versus escalating-dose methotrexate without leucovorin rescue during interim maintenance I in patients with newly diagnosed high-risk acute lymphoblastic leukemia. Available from: http://www.cancer.gov/clinicaltrials/COG-AALL0232[accessed 23.07.08]
  34. Tubergen DC, Bleyer A. The leukemias. In:  Behrman RE,  Kliegman RM,  Jenson HB editor. Nelson textbook of pediatrics. Philadelphia: Saunders; 2003;p. 1694–1698
  35. Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood. 1989;73:57–63
  36. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001;15:208–216
  37. Durrant IJ, Prentice HG, Richards SM. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical research council randomized trial UKALL XA. Medical research council working party on leukaemia in adults. British Journal of Haematology. 1997;99:84–92
  38. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863–871
  39. Linker C, Damon L, Ries C, et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. Journal of Clinical Oncology. 2002;20:2464–2471
  40. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. Journal of Clinical Oncology. 1993;11:1780–1786
  41. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646–1654

PII: S1521-6926(08)00070-4

doi: 10.1016/j.beha.2008.08.004

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 647-658 , December 2008

Article Tools

* Image Usage & Resolution